Brief: Autolus Therapeutics Presents Positive Obe-Cel Data
13/12/2021 12:24
Dec 13 (Reuters) - Autolus Therapeutics PLC AUTL.O :
* AUTOLUS THERAPEUTICS PRESENTS POSITIVE OBE-CEL DATA AT THE
63RD
ASH ANNUAL MEETING & EXPOSITION
* AUTOLUS THERAPEUTICS PLC - DUAL TARGETING AUTO1/22 SHOWS
DATA
CONSISTENT WITH HIGH LEVEL OF ACTIVITY AND GOOD ENGRAFTMENT
* AUTOLUS THERAPEUTICS PLC - OBE-CEL RESPONSE AND SAFETY
DATA FROM
PHASE 1B PORTION OF FELIX STUDY CONSISTENT WITH PHASE 1 ALLCAR19
STUDY
* AUTOLUS THERAPEUTICS PLC - OBE-CEL SHOWS SUSTAINED
DURABILITY OF
RESPONSE WITH MORPHOLOGICAL EFS OF 46% AT 24 MONTHS IN ALLCAR19
STUDY
Source text for Eikon: ID:nGNX9jWGpx
Further company coverage: AUTL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Autolus Therapeutics
See all newsBrief: Autolus Therapeutics PLC Unit Enters Master Service Agreement With AGC Biologics
Brief: Autolus Therapeutics Appoints Ryan Richardson To Board Of Directors
Brief: Nice Recommends Aucatzyl As A Treatment Option For Adult Patients With Lymphoblastic Leukemia
Brief: Autolus Therapeutics’ Car T Therapy Aucatzyl® (Obecabtagene Autoleucel) Granted European Marketing Authorization For Adult Patients
Brief: Autolus Therapeutics Announces Inducement Grants